Resources: Pillar 5: SGLT-2 inhibitors SGLT-2 inhibitors lower glucose by increasing urinary glucose excretion, reducing glucose toxicity, and often reducing insulin requirements, without directly increasing insulin
scar tissue formation at the injury site Anti-inflammatory down-regulates NF-B signaling, one of the key inflammatory pathways active in disc herniations Works in synergy with BPC-157 while BPC-157 creates the growth signals, TB-500 provides the cellular migration framework to execute the repair Protocol: Loading phase: 2.5mg5mg/week subcutaneous injection for 46 weeks Maintenance: 1.252.5mg/week ongoing Frequency: Single weekly injection or split into two 1.25mg injections across the week (both approaches work) The Synergy: Why Run Both Together BPC-157 and TB-500 work through different but complementary mechanisms
Of these, upregulations in phosphofructokinase and pyruvate kinase are of particular note, as these represent rate-limiting catalytic steps within the glycolytic pathway, which is a described result of GLP-1 receptor stimulation that ultimately results in augmented ATP production
Flexibility: Seasonal approaches accommodate natural variation in lifestyle and metabolic demands
Our board-certified providers specialize in personalized, science-based approach to help patients lose weight
